BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

With the first clinical data due on Mirati’s KRAS inhibitor next week, the market will get its first chance to justify -- or otherwise -- the large chunk of the company’s $3 billion valuation tied...
BioCentury | Sep 21, 2015
Finance

California raisin'

Mirati Therapeutics Inc. (NASDAQ:MRTX) has raised more money since moving to California and listing on NASDAQ about two years ago than the cancer company did in its prior 18 years of existence in Canada. On...
BC Week In Review | Dec 16, 2013
Clinical News

Mocetinostat: Phase II started

Mirati began an open-label Phase II trial to evaluate 70 and 90 mg oral mocetinostat plus azacitidine in about 30 patients with MDS. In 2H14, the company plans to start a Phase III trial with...
BC Extra | Oct 25, 2013
Financial News

Mirati raises $56.9 million in bumped-up follow-on

Mirati Therapeutics Inc. (NASDAQ:MRTX) raised $59.9 million through the sale of 3.3 million shares at $17.50 in a bumped-up follow-on underwritten by Jefferies; Leerink; and Piper Jaffray. Mirati (formerly MethylGene Inc. ) first proposed to raise...
BC Extra | Oct 17, 2013
Financial News

Portola, Mirati amend follow-ons

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Mirati Therapeutics Inc. (NASDAQ:MRTX) both amended follow-ons on Wednesday. Portola plans to sell 4.5 million shares in its offering. If sold at Portola's close of $22.83 on Tuesday, before the...
BC Week In Review | Jul 29, 2013
Financial News

Mirati Therapeutics financial update

Mirati voluntarily delisted from the Toronto Stock Exchange. The company will continue trading on NASDAQ. The company reincorporated in the U.S. from Canada and changed its name to Mirati from MethylGene Inc. in June (see...
BC Week In Review | Jul 15, 2013
Company News

Mirati Therapeutics cancer, infectious news

MethylGene Inc. completed its plans to reincorporate the company in the U.S. from Canada and change its name to Mirati. The biotech has applied to list its shares on NASDAQ and expects to start trading...
BC Week In Review | Jun 10, 2013
Clinical News

Mocetinostat: Additional Phase II data

Additional data from an open-label, North American Phase II trial in 72 patients showed that thrice-weekly 70-100 mg oral mocetinostat led to an ORR of 17% in patients with DLBCL (n=41) and 10% in patients...
BC Week In Review | Jun 10, 2013
Clinical News

Mocetinostat: Phase II data

An open-label, U.S. Phase II trial in 66 patients with MDS or AML showed that thrice-weekly oral mocetinostat plus azacitidine led to an ORR, defined as complete remission (CR), CR with incomplete blood count recovery...
BC Week In Review | May 20, 2013
Company News

MethylGene cancer, infectious news

MethylGene's board approved a proposal to reincorporate the company in the U.S., change its name to Mirati Therapeutics Inc. and list its shares on NASDAQ. The company said it plans to reincorporate in Delaware and...
Items per page:
1 - 10 of 206
BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

With the first clinical data due on Mirati’s KRAS inhibitor next week, the market will get its first chance to justify -- or otherwise -- the large chunk of the company’s $3 billion valuation tied...
BioCentury | Sep 21, 2015
Finance

California raisin'

Mirati Therapeutics Inc. (NASDAQ:MRTX) has raised more money since moving to California and listing on NASDAQ about two years ago than the cancer company did in its prior 18 years of existence in Canada. On...
BC Week In Review | Dec 16, 2013
Clinical News

Mocetinostat: Phase II started

Mirati began an open-label Phase II trial to evaluate 70 and 90 mg oral mocetinostat plus azacitidine in about 30 patients with MDS. In 2H14, the company plans to start a Phase III trial with...
BC Extra | Oct 25, 2013
Financial News

Mirati raises $56.9 million in bumped-up follow-on

Mirati Therapeutics Inc. (NASDAQ:MRTX) raised $59.9 million through the sale of 3.3 million shares at $17.50 in a bumped-up follow-on underwritten by Jefferies; Leerink; and Piper Jaffray. Mirati (formerly MethylGene Inc. ) first proposed to raise...
BC Extra | Oct 17, 2013
Financial News

Portola, Mirati amend follow-ons

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Mirati Therapeutics Inc. (NASDAQ:MRTX) both amended follow-ons on Wednesday. Portola plans to sell 4.5 million shares in its offering. If sold at Portola's close of $22.83 on Tuesday, before the...
BC Week In Review | Jul 29, 2013
Financial News

Mirati Therapeutics financial update

Mirati voluntarily delisted from the Toronto Stock Exchange. The company will continue trading on NASDAQ. The company reincorporated in the U.S. from Canada and changed its name to Mirati from MethylGene Inc. in June (see...
BC Week In Review | Jul 15, 2013
Company News

Mirati Therapeutics cancer, infectious news

MethylGene Inc. completed its plans to reincorporate the company in the U.S. from Canada and change its name to Mirati. The biotech has applied to list its shares on NASDAQ and expects to start trading...
BC Week In Review | Jun 10, 2013
Clinical News

Mocetinostat: Additional Phase II data

Additional data from an open-label, North American Phase II trial in 72 patients showed that thrice-weekly 70-100 mg oral mocetinostat led to an ORR of 17% in patients with DLBCL (n=41) and 10% in patients...
BC Week In Review | Jun 10, 2013
Clinical News

Mocetinostat: Phase II data

An open-label, U.S. Phase II trial in 66 patients with MDS or AML showed that thrice-weekly oral mocetinostat plus azacitidine led to an ORR, defined as complete remission (CR), CR with incomplete blood count recovery...
BC Week In Review | May 20, 2013
Company News

MethylGene cancer, infectious news

MethylGene's board approved a proposal to reincorporate the company in the U.S., change its name to Mirati Therapeutics Inc. and list its shares on NASDAQ. The company said it plans to reincorporate in Delaware and...
Items per page:
1 - 10 of 206